First, the relatively modest pCR rates with chemotherapy alone underscore the aggressive biology of HER2-positive tumor, while the significant benefit from combined chemotherapy and targeted therapy highlights the importance of anti-HER2 treatment. Here, ERBB2 is linked to neoplasm.